Quick answer
Caris Life Sciences, Inc. (CAI) reported revenue of $812.0M and net loss of $68.1M for the fiscal year ended 2025-12-31, up 97.0% from $412.3M the year before, per its 10-K filed with the SEC on 2026-03-03. Long-term debt stood at $378.4M.
Data as of 2025-12-31. Source: SEC EDGAR XBRL company facts (10-K/10-Q filings)
| Fiscal year | Revenue | Net income | Long-term debt |
|---|---|---|---|
| 2025 (FY ending 2025-12-31) | $812.0M | -$68.1M | $378.4M |
| 2024 (FY ending 2024-12-31) | $412.3M | -$281.9M | $373.1M |
| 2023 (FY ending 2023-12-31) | $306.1M | -$341.4M | — |
Related
- C revenue, net income and debt history (Citigroup Inc)
- CACI revenue, net income and debt history (Caci International Inc)
- CAH revenue, net income and debt history (Cardinal Health, Inc.)
- CARR revenue, net income and debt history (Carrier Global Corporation)
- CART revenue, net income and debt history (Maplebear Inc.)
- CASY revenue, net income and debt history (Casey’S General Stores, Inc.)
- CB revenue, net income and debt history (Chubb Limited)
- CBOE revenue, net income and debt history (Cboe Global Markets, Inc.)
Last updated 2026-10-16. Data only, not financial or tax advice.